TwoOncDocs

🩸 a podcast about heme/onc for health care providers | ☕️ short high yield episodes to supplement your board review resources | @SamArmstrongMD @DrKarineTawagi

[TwoOncDocs @TwoOncDocs]

🤔 Heading to #ASH26?

⭐️ Join us for a complimentary in-person Hematology Board Review for fellows & anyone prepping for boards 🩸

📅 Friday, December 11, 2026
🕗 8:00 AM–12:00 PM CT
📍 420 Julia St., New Orleans, LA
🔗 Register: https://t.co/PznLrha0Fi

[TwoOncDocs @TwoOncDocs]

@therealneel @OncLive @hemeoncfellow @HemOncFellows Thank you for sharing & GL with the final few weeks!!

[TwoOncDocs @TwoOncDocs]

We released our cheat sheet of highest yield topics last week for ABIM exams coming up Nov 17&18!

🫁 Onc:
GI 13.5%
Breast 13.5%
GU 12%
Thoracic 11.5%
Together, represent over 50%

🩸 Heme:
Neoplasms make up 35%
Prioritize leukemias, lymphomas, and plasma cell disorders

GL! 🙏🏼

[TwoOncDocs @TwoOncDocs]

Join us & @OncBrothers Dec 11 in New Orleans 8AM-12PM for a complimentary high yield interactive board review session on malignant & classical heme topics right before #ASHapalooza

Followed by a special career panel with our friend @rmistry91 from the @thefellowoncall🩸#ASH26

[Karine Tawagi MD @DrKarineTawagi]

📣 another FDA approval in APMS

➡️ MANY in 2026 inc. pluvicto & capivasertib

➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2)

➡️ rPFS 77% vs 56% (HR 0.48)

⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator

[Karine Tawagi MD @DrKarineTawagi]

Incredible to see work on the very rare RCC subtypes: collecting duct & renal medullary CA at #ESMO26

#REPRINT trial testing EV + P
🎯 22% ORR & 55% DCR overall ➡️ moving to stage 2!

Also very impt trials from @PavlosMsaouel in RMC on: ubamatamab, Sac-TMT, panitumumab…

[Karine Tawagi MD @DrKarineTawagi]

Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26:

🌟final KN564 @DrChoueiri
🌟PROs of RAMPART
🌟CA-IX PET
🌟cabo/atezo in metastatic papillary RCC @maughanonc
🌟EVP in RMC
🌟LACO-Stim CART
🌟KIM-1 @VincentWenxinXu
🌟PDL1 #CARE1
🌟LITESPARK011 QoL @DrDanielHeng

[Karine Tawagi MD @DrKarineTawagi]

💫#VOLGA: Durva + EV in cis-ineligible, like #EV303 but NO adjuvant EV here

⬆️ 2-year EFS (HR 0.51), OS (HR 0.58) & pCR (45% vs 10%)

Triplet arm OS not significant & ⬆️ tox

Less robust #s then EVP but how much benefit does adjuvant EV add? Can we use ctDNA/pCR to ��️? #ESMO26

[Karine Tawagi MD @DrKarineTawagi]

Incredible cancer breakthrough #ESMO26 w/ new benchmark in melanoma & huge advances for all future personalized tx that could extend to other cancers

🌟 Ph3 Intismeran autogene mRNA vaccine improved RFS by 42% w/ Pembro vs Pembro alone, distant mets reduced by 38%, similar AEs

[Karine Tawagi MD @DrKarineTawagi]

🔥 full house before #ESMO26 Presidential:

🔹#INTerpath001: Intismeran autogene + pembro vs pembro in resected melanoma

🔹#VOLGA: Periop durva ± treme + EV in MIBC

🔹#DeLLphi-305: Tarlatamab + durva vs durva as 1L maintenance in ES-SCLC

🔹Daro + ADT + RT in very high-risk PCa

[Sakditad “Tew” Saowapa, MD @SakditadMD]

Excited to join the Clinicals to Exam – Oncology Board Review during #ASH2026 in New Orleans on December 11!

Looking forward to strengthening my clinical knowledge, gaining valuable insights, and connecting with fellow hematology/oncology professionals!

#HemeOnc #Oncology #MedEd @OncUpdates @OncBrothers @TwoOncDocs #hematology

https://t.co/2nR5QJi2bH

[TwoOncDocs @TwoOncDocs]

C) In the NCCN the preferred 1L therapy for HR-positive, HER2-negative recurrent/metastatic disease is an AI combined with a CDK4/6 inhibitor; among these, the AI + ribociclib combination is specifically designated category 1, based on the OS benefit shown in the MONALEESA trials

[TwoOncDocs @TwoOncDocs]

We are back this week with our final #breastcancer series on metastatic breast cancer 🩷

A 62yo F presents with newly diagnosed ER-positive, HER2-negative metastatic breast cancer with asymptomatic bone and nodal disease.

Which of the following is a preferred tx?

[OncUpdates @OncUpdates]

🤩 #HemOnc Fellows, are you going to #ASH26? Join for a FREE board review!

👀 Here is a sneak peek of your board review day!

🗓️ In-person w/@OncBrothers + @TwoOncDocs
🔗 Register: https://t.co/nPGI7ojZ07

#OncTwitter #MedX #MedTwitter #ASH @HemOncFellows @hemeoncfellow

[OncUpdates @OncUpdates]

🤔Headed to #ASH26? Join for a FREE board review!

🗓️ In-person w/@OncBrothers + @TwoOncDocs
📅 Friday, Dec 11th
📍 Common House,New Orleans
🔗 Register: https://t.co/nPGI7okwPF

#OncTwitter #HemOnc #MedX #MedTwitter #ASH #MedEd @HemOncFellows @hemeoncfellow @ASH_hematology

[Paul H, PharmD, RPH @phsiao4]

Highly recommended! 💕 2026 update focusing on metastatic breast cancer @TwoOncDocs There is no better way to learn new Oncology meds other than treat them like new songs (listen frequently) 🎶 Learn from the BEST on proper pronunciations of Onc meds. https://t.co/t0ZKNSVDbj

[TwoOncDocs @TwoOncDocs]

Answer is C) Tamoxifen for 5 years (with or without ovarian function suppression. The addition of OFS to tamoxifen (or use of an AI plus OFS) is reserved for patients at higher risk - young age (≤35–40 years), high grade, or nodal involvement -based on the SOFT and TEXT trials.

[TwoOncDocs @TwoOncDocs]

Today part 2 of our breast cancer series is out on Localized #BreastCancer 🩷

A 39yo woman with pt1c (1.5cm) ER+ breast cancer undergoes a lumpectomy with SLNB.

Which of the following adjuvant endocrine therapies is preferred in PRE menopausal women?

[TwoOncDocs @TwoOncDocs]

The answer is D) all patients with TNBC should undergo germline testing

[TwoOncDocs @TwoOncDocs]

We are back with 2026 Breast Cancer updates! 🩷

In today’s episode, we cover an introduction on breast cancer, screening, prevention, DCIS, LCIS & more.

At what age range, should patients with triple negative breast cancer have genetic testing?

[Karine Tawagi MD @DrKarineTawagi]

Today 9/24/26 new approval in 2L clear cell mRCC with some caveats #LITESPARK011

💢 4mo PFS gain, higher ORR (53% vs 40%) & DOR (23 v 12mo)
💢 OS is not yet significant
💢 how does it perform post 1L IO/IO vs IO/TKI, weight of extra toxicity & optimal sequencing still unclear